8-KOther Events

EIDP, Inc. 8-K Report (Apr 24, 2001)

Filed April 24, 2001For Securities:CTA-PBCTA-PA

Summary

E.I. du Pont de Nemours and Company (DuPont) reported its first quarter 2001 earnings on April 24, 2001. The company's underlying earnings per share of $0.54 were down significantly by 36% compared to $0.85 in the prior year's first quarter. This decline was driven by a 9% decrease in segment sales, totaling $7.6 billion, attributed to both lower volumes (7% decrease) and a 2% decline in selling prices. Factors impacting profitability included a substantial reduction in Pharmaceuticals results, higher raw material costs, and unfavorable currency effects, particularly from the weaker euro and Japanese yen. In response to the challenging global economic slowdown, DuPont announced that it is undertaking business restructurings and personnel reductions. While these initiatives will result in one-time charges in the second quarter, they are aimed at better aligning resources and sharpening competitiveness. The company anticipates continued volume pressure and economic headwinds through the second quarter and potentially the second half of 2001, with ongoing efforts to manage costs and capital spending.

Key Highlights

  • 1First quarter 2001 underlying earnings per share were $0.54, a 36% decrease from $0.85 in Q1 2000.
  • 2Segment sales for Q1 2001 were $7.6 billion, down 9% from Q1 2000, due to 7% lower volume and 2% lower selling prices.
  • 3Underlying after-tax operating income (ATOI) decreased by 33% to $734 million.
  • 4Pharmaceuticals segment performance significantly impacted the overall decline, accounting for approximately one-third of the ATOI decrease.
  • 5Higher raw material costs ($165 million impact) and lower sales volume ($100 million impact) were key drivers of reduced ATOI, excluding Pharmaceuticals.
  • 6Adverse currency movements, primarily the weaker euro and Japanese yen, reduced segment sales by 3%.
  • 7DuPont is initiating business restructurings and personnel reductions to manage costs and improve competitiveness, with related charges expected in Q2 2001.

Frequently Asked Questions

The primary reasons for the significant decline in first quarter 2001 earnings were a combination of lower sales volumes across many segments, reduced selling prices, higher raw material costs, and a substantial underperformance in the Pharmaceuticals segment. Adverse currency exchange rates also played a role.

DuPont is implementing business restructurings and personnel reductions to better align resources and enhance competitiveness. They are also managing operating costs and capital spending in line with current economic conditions.

Currency fluctuations, particularly the weakening of the euro and Japanese yen against the U.S. dollar, negatively impacted DuPont's results. Adverse currency effects reduced worldwide segment sales by approximately 3%.

DuPont anticipates continued volume pressure in the second quarter due to the global economic slowdown, although sequential declines are expected to moderate. The company expects the strength of the U.S. dollar to continue to impact revenues in Europe and Asia. The outlook for the second half of 2001 remains uncertain, but key indicators suggest moderating declines in some markets. The Pharmaceuticals segment is expected to improve in the second quarter but remain at an ATOI loss, with a return to more normal sales and earnings anticipated in the second half.